

Product Name	Professional Indemnity and Excess Professional Indemnity
Insurers	Various
Responsible For	No
Manufacture	
Advised Sales	No
Product Type	Financial Lines
Availability	Manually underwritten / prior submit to insurers
Target Market	UK based commercial customers requiring cover for professional services and/or
	professional advice. Specifically, those that fall within the SSR Combined scheme
	risk appetite.
Non-Target	Non-Commercial customers
Market	
(Unsuitable	
Markets)	
Why Is This	SSR work with known insurers and products to ensure that covers offered are
Product Suitable	suitable for the risks insured. Wordings used cater for financial loss caused by the
	professional services rendered or professional advice given by the insured.
Are There Any	Yes – buyback coverage for higher risk elements may be offered, such as asbestos.
Optional Covers	
Distribution	SSR wholesale this product through other insurance intermediaries on behalf of
Methods	various insurers. This product can be obtained by SSR on a manual referral basis
	and the insurer used will be confirmed at time of quote.
Is This Product	Yes, this product is deemed to be providing fair value as it is specifically targeted in
Providing Fair	terms of coverage and function and is distributed via insurance intermediaries who
Value	understand the requirements of their clients.
Risk To Fair Value	Duplication of covers elsewhere or failure to purchase required optional elements.
Mitigation	Excessive commission or fees may undermine the value of the product as well.
	Care to be taken by distributors to ensure covers offered are not duplicating by
	other offerings. Commission levels charged by SSR and provided to distributors are
Oth an Inferrer 1	within market norms and monitored for fairness regularly.
Other Information	Product documents can be provided upon request which clarifies position of
To Consider	product on standard exclusions and limitations to product coverage.
	Incurrence produces their own Feir Value Statements and Target Market Statements
	Insurers produce their own Fair Value Statements and Target Market Statements
	which should take precedence over this document.

Published	September 2023
Planned review	September 2024